We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
04 May 2021 - 07 May 2021
Virtual Venue

22-Gene Genomic Classifier Validated in Recurrent Prostate Cancer Patients

By LabMedica International staff writers
Posted on 25 Feb 2021
Print article
Image: High-power photomicrograph of ductal adenocarcinoma (Prostate cancer) illustrating tall columnar cells with pale to clear cytoplasm and large ovoid nuclei (Photo courtesy of David J. Grignon, MD).
Image: High-power photomicrograph of ductal adenocarcinoma (Prostate cancer) illustrating tall columnar cells with pale to clear cytoplasm and large ovoid nuclei (Photo courtesy of David J. Grignon, MD).
When prostate cancer has been detected or has returned following initial treatment with surgery, radiation therapy and/or hormone therapy, it is said to be recurrent or relapsed. Treatment of recurrent prostate cancer depends on what treatment a patient has previously received and the extent of the cancer.

Some patients have only a rise in prostate-specific antigen (PSA) level as evidence of recurrent cancer. Other patients will have evidence of recurrent cancer on X-rays or scans. Patients who have prostate cancer that continues to grow despite hormone therapy are referred to as having hormone-refractory prostate cancer (HRPC).

An international team of Oncologists led by those at University of California San Francisco Medical Center (San Francisco, CA, USA) in an ancillary study used Decipher genomic classifier (GC) a 22 gene RNA-based signature (Decipher Biosciences Inc, San Diego, CA, USA) that generated GC scores from samples from a total of 352 men (median [interquartile range] age, 64.5 (60-70) years; 314 White [89.2%] participants) passed microarray quality control and comprised the final cohort for analysis, with median follow-up of 13 years. Patient GC scores were calculated on a continuous scale from 0 (lowest) to 1 (highest). Scores were then classified as low (42%), intermediate (38%), or high (20%) using previously established 0.45 and 0.60 as cutoffs.

The team reported that on multivariable analysis, the GC (continuous variable, per 0.1 unit) was independently associated with distant metastasis (DM) (hazard ratio [HR], 1.17; prostate cancer–specific mortality (PCSM) (HR, 1.39), and overall survival (OS) (HR, 1.17) after adjusting for age, race/ethnicity, Gleason score, T stage, margin status, entry prostate-specific antigen, and treatment arm. Although the original planned analysis was not powered to detect a treatment effect interaction by GC score, the estimated absolute effect of bicalutamide on 12-year OS was less when comparing patients with lower versus higher GC scores (2.4% versus 8.9%), which was further demonstrated in men receiving early salvage radiotherapy (sRT) at a prostate-specific antigen level lower than 0.7 ng/mL (−7.8% versus 4.6%).

Felix Y. Feng, MD, a Professor of Radiation Oncology and first author of the study, said, “Thus, our findings can be relatively quickly incorporated into clinical practice. For patients with prostate cancer recurrences following surgery, I believe that the Decipher test can be helpful to guide decisions regarding who should receive radiation alone or radiation with hormone therapy.”

The authors concluded that the ancillary validation study of the Decipher GC in a randomized trial cohort demonstrated association of the GC with DM, PCSM, and OS independent of standard clinicopathologic variables. These results suggest that not all men with biochemically recurrent prostate cancer after surgery benefit equally from the addition of hormone therapy to sRT. The study was published on February 11, 2021 in the journal JAMA Oncology.

Related Links:
University of California San Francisco Medical Center
Decipher Biosciences Inc


New
Gold Supplier
SARS-CoV-2 Rapid Test
Vivalytic SARS-CoV-2 Rapid 39 Minute Test
New
COVID-19 Antigen Test (Swab)
Rapid COVID-19 Antigen Test (Swab)
SARS-CoV-2/Influenza A & B/RSV Test
BIOSYNEX® AMPLIQUICK® SARS-COV-2 and Respiratory Triplex
Hematology Analyzer
DxH 560 AL

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: The EZ DNA Methylation-Direct Kit (Photo courtesy of Zymo Research)

Leukocyte Epigenomics and Artificial Intelligence Predict Late-Onset Alzheimer’s Disease

Alzheimer’s Disease (AD) is the most common form of age-related dementia, accounting for 60%–80% of such cases. The disorder causes a wide range of significant mental and physical disabilities, with profound... Read more

Industry

view channel
Image: The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing (Photo courtesy of Mobidiag Ltd.)

Hologic to Acquire Mobidiag to Strengthen Diagnostic Testing Business

Hologic, Inc. (Marlborough, MA, USA) has signed a definitive agreement to acquire Mobidiag Ltd. (Espoo, Finland) in a USD 795 million transaction that will accelerate the global growth of Mobidiag’s differentiated... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.